SAFETY AND EFFICACY OF RECOMBINANT HIRUDIN (CGP-39393) VERSUS HEPARIN IN PATIENTS WITH STABLE ANGINA UNDERGOING CORONARY ANGIOPLASTY

被引:114
作者
VANDENBOS, AA
DECKERS, JW
HEYNDRICKX, GR
LAARMAN, GJ
SURYAPRANATA, H
ZIJLSTRA, F
CLOSE, P
RIJNIERSE, JJMM
BULLER, HR
SERRUYS, PW
机构
[1] ERASMUS UNIV ROTTERDAM,DIV CARDIOL,THORAXCTR,DR MOLEWATERPLEIN 40,3015 GD ROTTERDAM,NETHERLANDS
[2] UNIV AMSTERDAM,ACAD MED CTR,DEPT INTERNAL MED,1105 AZ AMSTERDAM,NETHERLANDS
[3] HOSP DE KLOKKENBERG,DEPT CARDIOL,BREDA,NETHERLANDS
[4] UNIV HOSP DIJKZIGT,ROTTERDAM,NETHERLANDS
[5] ONZE LIEVE VROUWE KLIN,CTR CARDIOVASC,AALST,BELGIUM
[6] ONZE LIEVE VROUW HOSP,AMSTERDAM DEPT INTERVENT CARDIOL,AMSTERDAM,NETHERLANDS
[7] HOSP WEEZENLANDEN,DEPT CARDIOL,ZWOLLE,NETHERLANDS
[8] CIBA GEIGY AG,CH-4002 BASEL,SWITZERLAND
关键词
ANTICOAGULANTS; CORONARY ARTERY DISEASE; CLINICAL TRIALS;
D O I
10.1161/01.CIR.88.5.2058
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Enhanced thrombin activity has been associated with acute and long-term complications following balloon angioplasty (percutaneous transluminal coronary angioplasty (PTCA). We evaluated, in a 2-to-1 randomized, double-blind trial, the effects of recombinant hirudin, CGP 39 393, relative to unfractionated sodium heparin on periprocedural events, bleeding, early angiographic outcome, and coagulation in 113 patients with stable angina undergoing PTCA. Methods and Results. Prior to PTCA, 20 mg CGP 39 393 was administered as a bolus, followed by continuous infusion at a rate of 0.16 mg . kg-1 . h-1, or 10 000 IU sodium heparin was administered as a bolus and continued at a rate of 12 IU . kg-1 . h-1 for 24 hours. Infusion was adjusted to activated partial thromboplastin time (APTT) levels. ST segment was monitored for 24 hours, and angiograms were analyzed with quantitative technique (QCA). In 74 CGP 39 393- and 39 heparin-treated patients, 132 lesions were dilated. Myocardial infarction and/or emergency coronary bypass surgery occurred in 1 (1.4%) CGP 39 393 patient compared with 4 (10.3%) heparin patients (relative risk, 7.6; 95% confidence interval, 0.9, 65.6). At 24 hours, complete perfusion was present in 91% heparin and 100% CGP 39 393 patients. Significant ST segment displacement was found in 11% of heparin versus 4% of CGP 39 393 subjects. Bleeding occurred only at the puncture site in 4 CGP 39 393-treated patients. QCA did not reveal significant differences between the groups. APTT values were more often in the target range and more stable in CGP 39 393 patients. Levels of thrombin-antithrombin III complexes, prothrombin fragment F1+2, and fibrinopeptide A indicated that CGP 39 393 was an effective inhibitor of thrombin activity. Conclusions. CGP 39 393 can safely be administered to patients undergoing elective PTCA for stable anginal symptoms and may have a more favorable anticoagulant profile than heparin.
引用
收藏
页码:2058 / 2066
页数:9
相关论文
共 39 条
  • [1] Austen W. G., 1975, CIRCULATION, V51, P7
  • [2] ASPIRIN AND DIPYRIDAMOLE IN THE PREVENTION OF ACUTE CORONARY-THROMBOSIS COMPLICATING CORONARY ANGIOPLASTY
    BARNATHAN, ES
    SCHWARTZ, JS
    TAYLOR, L
    LASKEY, WK
    KLEAVELAND, JP
    KUSSMAUL, WG
    HIRSHFELD, JW
    [J]. CIRCULATION, 1987, 76 (01) : 125 - 134
  • [3] FREQUENCY OF INTRACORONARY FILLING DEFECTS BY ANGIOGRAPHY IN ANGINA-PECTORIS AT REST
    CAPONE, G
    WOLF, NM
    MEYER, B
    MEISTER, SG
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1985, 56 (07) : 403 - 406
  • [4] THROMBOLYSIS IN MYOCARDIAL-INFARCTION (TIMI) TRIAL, PHASE-I - A COMPARISON BETWEEN INTRAVENOUS TISSUE PLASMINOGEN-ACTIVATOR AND INTRAVENOUS STREPTOKINASE - CLINICAL FINDINGS THROUGH HOSPITAL DISCHARGE
    CHESEBRO, JH
    KNATTERUD, G
    ROBERTS, R
    BORER, J
    COHEN, LS
    DALEN, J
    DODGE, HT
    FRANCIS, CK
    HILLIS, D
    LUDBROOK, P
    MARKIS, JE
    MUELLER, H
    PASSAMANI, ER
    POWERS, ER
    RAO, AK
    ROBERTSON, T
    ROSS, A
    RYAN, TJ
    SOBEL, BE
    WILLERSON, J
    WILLIAMS, DO
    ZARET, BL
    BRAUNWALD, E
    [J]. CIRCULATION, 1987, 76 (01) : 142 - 154
  • [5] DYNAMIC THROMBOSIS AND THROMBOLYSIS - ROLE OF ANTITHROMBINS
    CHESEBRO, JH
    FUSTER, V
    [J]. CIRCULATION, 1991, 83 (05) : 1815 - 1817
  • [6] ABRUPT CORONARY-ARTERY OCCLUSION DURING PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY
    DEFEYTER, PJ
    DEJAEGERE, PPT
    MURPHY, ES
    SERRUYS, PW
    [J]. AMERICAN HEART JOURNAL, 1992, 123 (06) : 1633 - 1642
  • [7] ACUTE CORONARY-ARTERY OCCLUSION DURING AND AFTER PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY - FREQUENCY, PREDICTION, CLINICAL COURSE, MANAGEMENT, AND FOLLOW-UP
    DEFEYTER, PJ
    VANDENBRAND, M
    JAARMAN, G
    VANDOMBURG, R
    SERRUYS, PW
    SURYAPRANATA, H
    [J]. CIRCULATION, 1991, 83 (03) : 927 - 936
  • [8] INCIDENCE AND CONSEQUENCES OF PERIPROCEDURAL OCCLUSION - THE 1985-1986 NATIONAL HEART, LUNG, AND BLOOD INSTITUTE PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY REGISTRY
    DETRE, KM
    HOLMES, DR
    HOLUBKOV, R
    COWLEY, MJ
    BOURASSA, MG
    FAXON, DP
    DORROS, GR
    BENTIVOGLIO, LG
    KENT, KM
    MYLER, RK
    [J]. CIRCULATION, 1990, 82 (03) : 739 - 750
  • [9] PERCUTANEOUS TRANS-LUMINAL CORONARY ANGIOPLASTY - REPORT OF COMPLICATIONS FROM THE NATIONAL-HEART-LUNG-AND-BLOOD-INSTITUTE PTCA REGISTRY
    DORROS, G
    COWLEY, MJ
    SIMPSON, J
    BENTIVOGLIO, LG
    BLOCK, PC
    BOURASSA, M
    DETRE, K
    GOSSELIN, AJ
    GRUNTZIG, AR
    KELSEY, SF
    KENT, KM
    MOCK, MB
    MULLIN, SM
    MYLER, RK
    PASSAMANI, ER
    STERTZER, SH
    WILLIAMS, DO
    [J]. CIRCULATION, 1983, 67 (04) : 723 - 730
  • [10] EFFECT OF 18-HOUR TO 24-HOUR HEPARIN ADMINISTRATION FOR PREVENTION OF RESTENOSIS AFTER UNCOMPLICATED CORONARY ANGIOPLASTY
    ELLIS, SG
    ROUBIN, GS
    WILENTZ, J
    DOUGLAS, JS
    KING, SB
    [J]. AMERICAN HEART JOURNAL, 1989, 117 (04) : 777 - 782